Targeted drug delivery by thermally responsive polymers

Advanced Drug Delivery Reviews

Volumn 54, Issue 5, 2002, Pages 613-630

  Chilkoti, Ashutosh ^a   Dreher, Matthew R ^a   Meyer, Dan E ^a   Raucher, Drazen ^b  

^a USA   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Cancer therapy; Elastin like polypeptide; Hyperthermia; Lower critical solution temperature; pH controlled release; Poly(N isopropylacrylamide); Targeted drug delivery; Thermally responsive polymer; Tumor

Indexed keywords

CELL CULTURE; POLYMERS; POLYPEPTIDES; TOXICITY; TUMORS;

THERMAL TARGETING;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; DOXORUBICIN ELASTIN LIKE POLYPEPTIDE CONJUGATE; DRUG CARRIER; ELASTIN LIKE POLYPEPTIDE; POLY(N ISOPROPYLACRYLAMIDE CO ACRYLAMIDE); POLYMER; RADIOISOTOPE ELASTIN LIKE POLYPEPTIDE CONJUGATE; RHODAMINE POLYMER CONJUGATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL CULTURE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; HUMAN; HYPERTHERMIA; ISOTOPE LABELING; MACROMOLECULE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TEMPERATURE DEPENDENCE; THERMAL ANALYSIS; TUMOR CELL LINE; TUMOR LOCALIZATION;

ACRYLIC RESINS; ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELASTIN; FLUORESCENCE; HEATING; HUMANS; PEPTIDES; POLYMERS; TUMOR CELLS, CULTURED;

EID: 0037072528     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00041-8     Document Type: Review

References (66)

1. http://seer.cancer.gov/, Surveillance Epidemiology and End Results, (2002).
2. Jain R.K. Delivery of molecular medicine to solid tumors. Science. 271:1996;1079-1080.
3. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271:1994;58-65.
4. Hauck M.L., Dewhirst M.W., Zalutsky M.R. Enhancement of radiolabeled monoclonal antibody uptake in tumors with local hyperthermia. Torchilin V., Handbook of Targeted Delivery of Imaging Agents. 1995;335-361 CRC Press, Boca Raton, FL.
5. Torchilin V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul. 15:1998;1-19.
6. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 3:1992;175-210.
7. Allen T.M. Liposomal drug formulations - rationale for development and what we can expect in the future. Drugs. 56:1998;747-756.
8. Langer R. Drug delivery and targeting. Nature. 392:1998;5-10.
9. Jones M., Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48:1999;101-111.
10. Minko T., Kopečková P., Kopeček J. Efficacy of the chemotherapeutic action of hpma copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer. 86:2000;108-117.
11. Cassidy J., Duncan R., Morrison G.J., Strohalm J., Plocova D., Kopecek J., Kaye S.B. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat-tumor model. Biochem. Pharmacol. 38:1989;875-879.
12. Shiah J.G., Sun Y.G., Peterson C.M., Kopecek J. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma ovcar-3 xenografts. J. Controlled Release. 61:1999;145-157.
13. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers - advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 3:1992;351-362.
14. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular-weights after intravenous administration to mice. J. Pharm. Sci. 83:1994;601-606.
15. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7:1990;339-346.
16. Yeung T.K., Hopewell J.W., Simmonds R.H., Seymour L.W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., Ulbrich K. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates - an experimental study in the rat. Cancer Chemother. Pharmacol. 29:1991;105-111.
17. Seymour L.W., Duncan R., Kopečková P., Kopeček J. Daunomycin-N-(2-hydroxypropyl)methacrylamide and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates - toxicity reduction by improved drug-delivery. Cancer Treat. Rev. 14:1987;319-327.
18. Duncan R., Coatsworth J.K., Burtles S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol. 17:1998;93-104.
19. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:1986;6387-6392.
20. Kopeček J., Kopečková P., Minko T., Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:2000;61-81.
21. Minko T., Kopečková P., Pozharov V., Kopeček J. HPMA copolymer bound adriamycin overcomes mdr1 gene encoded resistance in a human ovarian carcinoma cell line. J. Controlled Release. 54:1998;223-233.
22. Ryser H.J.P., Shen W.C. Conjugation of methotrexate to poly(l-lysine) increases drug transport and overcomes drug-resistance in cultured-cells. Proc. Natl. Acad. Sci. USA. 75:1978;3867-3870.
23. Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug-resistance in a rat hepatoma. Cancer Res. 53:1993;4238-4242.
24. Št'astný M., Strohalm J., Plocová D., Ulbrich K., Říhová B. A possibility to overcome p-glycoprotein (pgp)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer. 35:1999;459-466.
25. Urry D.W. Free energy transduction in polypeptides and proteins based on inverse temperature transitions. Prog. Biophys. Mol. Biol. 57:1992;23-57.
26. Schild H. Poly(NIPAAm): experiment, theory, and applications. Prog. Polym. Sci. 17:1992;163-249.
27. Urry D.W. Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. J. Phys. Chem. B. 101:1997;11007-11028.
28. Turner P.F. Mini-annular phased-array for limb hyperthermia. IEEE Trans. Microwave Theory Tech. 34:1986;508-513.
29. Samulski T.V., Kapp D.S., Fessenden P., Lohrbach A. Heating deep seated eccentrically located tumors with an annular phased-array system - a comparative clinical-study using 2 annular array operating configurations. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;83-94.
30. Fessenden P., Lee E.R., Anderson T.L., Strohbehn J.W., Meyer J.L., Samulski T.V., Marmor J.B. Experience with a multitransducer ultrasound system for localized hyperthermia of deep tissues. IEEE Trans. Biomed. Eng. 31:1984;126-135.
31. Dewhirst M.W., Prosnitz L., Thrall D., Prescott D., Clegg S., Charles C., MacFall J., Rosner G., Samulski T., Gillette E., LaRue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin. Oncol. 24:1997;616-625.
32. Dewhirst M.W., Tso C.Y., Oliver R., Gustafson C.S., Secomb T.W., Gross J.F. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int. J. Radiat. Oncol. Biol. Phys. 17:1989;91-99.
33. Engin K. Biological rationale and clinical experience with hyperthermia. Control. Clin. Trials. 17:1996;316-342.
34. Vaupel P., Kallinoqwski F. Physiological effects of hyperthermia. Recent Results Cancer Res. 104:1987;71-109.
35. Feyerabend T., Steeves R., Wiedemann G.J., Richter E., Robins H.E. Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res. 17:1997;2895-2897.
36. Issels R. Hyperthermia combined with chemotherapy - biological rationale, clinical application, and treatment results. Onkologie. 22:1999;374-381.
37. J.P. Johnson, J.N. Bruce, Angiogenesis in human gliomas: Prognostic and therapeutic applications, Regul. Angiogenesis (1997) 29-46.
38. Dewhirst M.W. Thermal dosimetry. Seegenschmiedt M.H., Fessenden P., Vernon C.C., Principles and Practice of Thermoradiotherapy and Thermochemotherapy. Vol. 1:1995;123-136 Springer-Verlag, Berlin.
39. Urry D.W., Luan C.-H., Parker T.M., Gowda D.C., Prasad K.U., Reid M.C., Safavy A. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J. Am. Chem. Soc. 113:1991;4346-4348.
40. Chiklis C.K., Grasshof J.M. Swelling of thin films. I. Acrylamide-N-isopropylacrylamide copolymers in water. J. Polym. Sci. 8:1970;1617-1626.
41. Taylor L.D., Cerankowski L.D. Preparation of films exhibiting a balanced temperature dependence to permeation by aqueous solutions - a study of lower cosolute behavior. J. Polym. Sci., Polym. Chem. 13:1975;2551-2570.
42. Priest J.H., Murray S.L., Nelson R.J., Hoffman A.S. Lower critical solution temperatures of aqueous copolymers of N-isopropylacrylamide and other N-substituted acrylamides. ACS Symposium Ser. 350:1987;255-264.
43. Meyer D.E., Shin B.C., Kong G.A., Dewhirst M.W., Chilkoti A. Drug targeting using thermally responsive polymers and local hyperthermia. J. Controlled Release. 74:2001;213-224.
44. Meyer D.E., Chilkoti A. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules. 3:2002;357-367.
45. McPherson D.T., Xu J., Urry D.W. Product purification by reversible phase transition following Escherichia coli expression of genes encoding up to 251 repeats of the elastomeric pentapeptide gvgvp. Protein Expr. Purif. 7:1996;51-57.
46. Meyer D.E., Chilkoti A. Purification of recombinant proteins by fusion with thermally responsive polypeptides. Nat. Biotechnol. 17:1999;1112-1115.
47. Meyer D.E., Kong G.A., Dewhirst M.W., Zalutsky M.R., Chilkoti A. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res. 61:2001;1548-1554.
48. Urry D.W., Trapane T.L., Prasad K.U. Phase-structure transitions of the elastin polypentapeptide-water system within the framework of composition-temperature studies. Biopolymers. 24:1985;2345-2356.
49. Schild H.G., Tirrell D.A. Microcalorimetric detection of lower critical solution temperatures in aqueous polymer solutions. 94:1990;4352-4356.
50. Durbin P.W., Jeung N., Kullgren B., Clemons G.K. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. 63:1992;427-442.
51. Barbee R.W., Perry B.D., Re R.N., Murgo J.P. Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. 263:1992;R728-R733.
52. Wu N.Z., Klitzman B., Rosner G., Needham D., Dewhirst M.W. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvasc. Res. 46:1993;231-253.
53. Raucher D., Chilkoti A. Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. Cancer Res. 61:2001;7163-7170.
54. Kaneko T., Willner D., Monkovic I., Knipe J.O., Braslawsky G.R., Greenfield R.S., Vyas D.M. New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjug. Chem. 2:1991;133-141.
55. Kong G.H., Dewhirst M.W. Hyperthermia and liposomes. Int. J. Hyperthermia. 15:1999;345-370.
56. Yuk S.H., Bae Y.H. Phase-transition polymers for drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 16:1999;385-423.
57. Galaev I.Y., Mattiasson B. 'Smart' polymers and what they could do in biotechnology and medicine. Trends Biotechnol. 17:1999;335-339.
58. Panchagnula R., Dey C.S. Monoclonal antibodies in drug targeting. J. Clin. Pharm. Ther. 22:1997;7-19.
59. Zhu H., Baxter L.T., Jain R.K. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J. Nucl. Med. 38:1997;731-741.
60. Oleson J.R., Samulski T.V., Leopold K.A., Clegg S.T., Dewhirst M.W., Dodge R.K., George S.L. Sensitivity of hyperthermia trial outcomes to temperature and time - implications for thermal goals of treatment. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;289-297.
61. Leopold K.A., Dewhirst M., Samulski T., Harrelson J., Tucker J.A., George S.L., Dodge R.K., Grant W., Clegg S., Prosnitz L.R., Oleson J.R. Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft-tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;989-998.
62. M. Dewhirst, T. Samulski, Hyperthermia in the treatment of cancer, Current Concepts (1988) 1-49.
63. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
64. Reubi J. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med. 41:1997;63-70.
65. Reubi J.C., Laissue J., Krenning E., Lamberts S.W.J. Somatostatin receptors in human cancer - incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 43:1992;27-35.
66. Mammen M., Choi S., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. Engl. 37:1998;2755-2794.